Related Experiment Video
Updated: Feb 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer
A Fucic1, A Aghajanyan2, Z Culig3
1Institute for Medical Research and Occupational Health, Ksaverska c 2, 10000, Zagreb, Croatia. afucic@imi.hr.
Abstract:
Large investments by pharmaceutical companies in the development of new antineoplastic drugs have not been resulting in adequate advances of new therapies. Despite the introduction of new methods, technologies, translational medicine and bioinformatics, the usage of collected knowledge is unsatisfactory. In this paper, using examples of pancreatic ductal adenocarcinoma (PaC) and castrate-resistant prostate cancer (CRPC), we proposed a concept showing that, in order to improve applicability of current knowledge in oncology, the re-clustering of clinical and scientific data is crucial. Such an approach, based on systems oncology, would include bridging of data on biomarkers and pathways between different cancer types. Proposed concept would introduce a new matrix, which enables combining of already approved therapies between cancer types. Paper provides a (a) detailed analysis of similarities in mechanisms of etiology and progression between PaC and CRPC, (b) diabetes as common hallmark of both cancer types and (c) knowledge gaps and directions of future investigations. Proposed horizontal and vertical matrix in cancer profiling has potency to improve current antineoplastic therapy efficacy. Systems biology map using Systems Biology Graphical Notation Language is used for summarizing complex interactions and similarities of mechanisms in biology of PaC and CRPC.
Insights
Re-clustering cancer data by analyzing similarities between pancreatic ductal adenocarcinoma and castrate-resistant prostate cancer can improve antineoplastic drug therapies. This systems oncology approach bridges knowledge for better treatment efficacy.
Area of Science:
- Oncology
- Systems Biology
- Translational Medicine
Background:
- Pharmaceutical investments in antineoplastic drugs yield limited therapeutic advances.
- Current knowledge application in oncology remains unsatisfactory despite technological progress.
- Pancreatic ductal adenocarcinoma (PaC) and castrate-resistant prostate cancer (CRPC) serve as models for exploring data re-clustering.
Purpose of the Study:
- To propose a concept for improving the applicability of current oncology knowledge through data re-clustering.
- To introduce a novel matrix for combining therapies across different cancer types.
- To analyze similarities between PaC and CRPC, including shared etiological mechanisms and diabetes as a hallmark.
Main Methods:
- Systems oncology approach for data re-clustering.
- Bridging data on biomarkers and pathways between different cancer types.
- Analysis of etiological and progression mechanisms in PaC and CRPC.
- Utilizing Systems Biology Graphical Notation Language for mapping biological interactions.
Main Results:
- Identified similarities in etiology and progression mechanisms between PaC and CRPC.
- Highlighted diabetes as a common hallmark in both cancer types.
- Proposed a new matrix for combining approved therapies across cancer types.
- Detailed knowledge gaps and future research directions.
Conclusions:
- Re-clustering clinical and scientific data is crucial for enhancing current oncology knowledge applicability.
- A systems oncology approach, bridging data across cancer types, can improve antineoplastic therapy efficacy.
- The proposed horizontal and vertical matrix offers potential for improved cancer profiling and treatment.
Related Concept Videos
Treatment Resistant Cancers
Design Example: Strain Gauge Bridge or Wheatstone Bridge
Wheatstone Bridge
Thus, for accurate resistance measurements, a...
Bridge rectifier
Operationally, the bridge rectifier allows current flow through two of its diodes during each...
Cross-bridge Cycle
Resistivity

